05:08 PM EDT, 07/15/2025 (MT Newswires) -- Gain Therapeutics ( GANX ) said late Tuesday it plans a public offering of common shares and warrants to purchase common shares.

The company will grant underwriters a 30-day overallotment option to buy up to an additional 15% of the common shares and warrants offered, according to a statement.

Gain Therapeutics ( GANX ) plans to use the net proceeds to advance clinical and nonclinical development of its GT-02287 drug candidate to treat neurodegenerative diseases, as well as for general corporate purposes, the company said.

Shares fell 14.7% during after-hours trading.